Clicky

Acurx Pharmaceuticals, Inc.(ACXP)

Description: Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.


Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Gram Positive Bacteria Methicillin Vancomycin Penicillins Antibiotic Resistant Bacteria Glycopeptide Antibiotics

Home Page: www.acurxpharma.com

ACXP Technical Analysis

259 Liberty Avenue
Staten Island, NY 10305
United States
Phone: 917-533-1469


Officers

Name Title
Mr. Robert J. DeLuccia Co-Founder & Exec. Chairman
Mr. David P. Luci CPA, CPA, Esq., J.D. Corp. Sec., Co-Founder, Pres, CEO & Director
Mr. Robert G. Shawah CPA, CPA Co-Founder & CFO

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.3934
Price-to-Sales TTM: 0
IPO Date: 2021-06-25
Fiscal Year End: December
Full Time Employees: 4
Back to stocks